GT BIOPHARMA INC GTBP
ASignal's systematic analysis rates GTBP as Bearish.
Reflects the latest available analysis · analyzed Nov 17, 2026
The case on GTBP
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Cash-rich balance sheet with no debt
- Current ratio above 2.5 indicates strong short-term liquidity
- Extremely oversold RSI near 9 suggests potential for mean reversion
- Severely negative return on equity and return on assets
- Negative operating and free cash flow trends
- Lack of revenue and earnings growth data
- MACD below signal line with negative histogram
- Price momentum strongly negative
- Low news coverage and zero Reddit mentions indicate minimal market interest
See the full verdict on GTBP
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes GTBP
Most investors never get a second opinion, let alone several. ASignal runs GTBP past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.